netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
  • CONTACT US
No announcement available or all announcement expired.
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
  • CONTACT US

Glycotest Update

Jun 26, 2017
-
Glycotest, News, RNS Announcements

London, UK – June 26th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, provides an update on the series A fundraising being undertaken by its portfolio company Glycotest, a US-based diagnostics company, as outlined in the Circular issued to shareholders following the Company’s placing and subscription of new shares on 26 May 2017 (the “Circular”).

The Company continues to anticipate closing the Series A round within the second half of 2017, but does not now expect to sign the relevant documentation by the end of June 2017, as was previously stated as the Company’s aim in the Circular.

As at 31 December 2016 the NetScientific had invested £2.4 million in Glycotest. The Company expects that the delay will lead to an increase in its £0.5m expected spend in Glycotest in 2017, as stated in the Circular, but with overall spend remaining under £1.0m in 2017.

# # #

For more information, please contact:

NetScientific
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800

Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson /
Chris Welsh / Laura Thornton

Tel: +44 (0)20 3709 5700
netscientific@consilium-comms.com
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600

About NetScientific

NetScientific is an IP commercialisation group focused on healthcare with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

About Glycotest

Glycotest is a US based diagnostics company, developing biomarkers for clinical laboratory
services used in the diagnosis of liver cancers and fibrosis-cirrhosis, which the Directors
believe represents a $1 billion market opportunity. Its blood-based biomarkers take advantage
of sugar-related disease signals and the company has issued patents to over 50 serum proteins
with sugar structures that are altered in liver disease. The biomarkers are being developed into
tests and test panels intended for the surveillance of patients with serious liver disease.

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
Glycotest™ Strengthens its Intellectual Property Reach by Expanding its United States, European and Australian Patent Portfolio
NEXT POST →
Results of AGM

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
Glycotest Update - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT